This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
The first description of autoimmune hepatitis (AIH) dates to 1950, when Ian Waldenström of Sweden reported cases of chronic liver disease with jaundice and hypergammaglobulinemia in young women. Because a clinical picture similar to systemic lupus erythematosus (SLE) was observed in many of these patients, Joske and King named the disease 'lupoid hepatitis' in 1956. MacKay and colleagues (1956) subsequently systematized the characteristic findings of serum antinuclear antibody (ANA) positivity and hyper-IgG-emia, suggesting that the disease was caused by immune-mediated injury.
In the 1960s–70s, corticosteroid therapy was introduced and dramatic biochemical and clinical responses were confirmed, strongly supporting an autoimmune mechanism. In 1965, Cook et al. demonstrated the survival benefit of corticosteroid monotherapy in a randomized controlled trial, and it was subsequently confirmed that combination therapy with azathioprine (AZA) was equally effective while reducing steroid side effects. In the 1970s, research groups including Solberg, Mistilis, and Mackay systematized liver histological findings (interface hepatitis, plasma cell infiltration) as diagnostic criteria.
Because the name 'lupoid hepatitis' caused confusion with SLE, the official name was changed to 'autoimmune hepatitis' when the International Autoimmune Hepatitis Group (IAIHG) was founded in 1992. In the same year, Johnson and McFarlane published the IAIHG diagnostic scoring system (original scoring system), standardizing diagnosis. This scoring system was revised in 1999 and is still used for research purposes. For ease of clinical application, Hennes et al. proposed the simplified scoring system in 2008, which is now the most widely used in clinical practice. In the 2010s, genome-wide association studies (GWAS) revealed that, in addition to HLA, many non-HLA loci such as SH2B3 and CARD10 are associated with AIH susceptibility. In 2019, AASLD and EASL each updated their practice guidelines, expanding the use of budesonide and clarifying mycophenolate mofetil (MMF) as second-line treatment and the criteria for liver transplantation.
AIH is an autoimmune liver disease that develops when environmental triggers precipitate a breakdown of immune self-tolerance (immune tolerance) in genetically susceptible individuals. The exact initial triggering mechanism has not yet been fully elucidated, but the following factors are understood to act in combination.
Viral infection: several viruses are associated with triggering or exacerbating AIH. Cases of AIH triggered by hepatitis A virus (HAV) and hepatitis E virus (HEV) have been reported, and in particular an immune cross-reactivity (molecular mimicry) mechanism has been proposed. Epstein-Barr virus (EBV), cytomegalovirus (CMV), and varicella-zoster virus (VZV) are also associated with AIH onset or exacerbation. Many cases of AIH onset after SARS-CoV-2 infection have also been reported.
Drug-induced autoimmune hepatitis (DIAIH): several drugs can cause an AIH-like syndrome. Minocycline and nitrofurantoin are known to be the most common causes, and interferon-α, atorvastatin, methyldopa, halothane, infliximab, ipilimumab, and others have also been reported. Unlike true DIAIH, which mostly goes into remission after drug discontinuation, some drugs trigger genuine AIH that requires immunosuppressive treatment even after the drug is stopped.
Autoantigen exposure: excessive exposure of liver autoantigens due to abnormal cell death (cell necrosis, oxidative stress) or abnormal autophagy can cause a breakdown of self-tolerance. Known major autoantigens in AIH include the asialoglycoprotein receptor (ASGPR), soluble liver antigen/liver-pancreas antigen (SLA/LP, the SEPSECS gene product), and CYP2D6 (the LKM-1 antigen).
Gut microbiota abnormalities: recent studies have observed reduced gut microbiota diversity and increases or decreases in specific species in AIH patients, raising the possibility that dysregulated immune regulation via the gut-liver axis is involved in the development of AIH.
AIH is not a single-gene disease but a complex multifactorial genetic disease, and the HLA (human leukocyte antigen) locus is central to genetic susceptibility. HLA-DR3 (DRB1*03:01) and HLA-DR4 (DRB1*04:01) are best known as AIH susceptibility alleles in Northern European white populations. In East Asians, including Koreans, HLA-DR4 (DRB1*04:05) is the main risk allele, and HLA-DR3 is relatively rare.
HLA-DR3–associated AIH develops at a younger age, has a relatively poorer treatment response, a higher relapse rate after remission, and more often requires liver transplantation. In contrast, HLA-DR4–associated AIH tends to occur in older patients, is commonly accompanied by peripheral arthritis, and tends to respond well to steroid treatment.
In studies of non-HLA loci, the +49A/G polymorphism of the CTLA-4 (cytotoxic T-lymphocyte antigen-4) gene has been reported in many studies to be associated with AIH susceptibility. CTLA-4 is an inhibitory molecule of T cell co-stimulation, and CTLA-4 dysfunction leads to T cell hyperactivation. The C1858T polymorphism of the PTPN22 gene (protein tyrosine phosphatase, non-receptor type 22, lymphoid) is also reported in AIH as a risk variant shared with several autoimmune diseases.
Genome-wide association studies (GWAS) have confirmed that loci such as SH2B3 (JAK-STAT signaling regulation), CARD10 (NF-κB signaling), and SPIB (immune cell transcription factor) are associated with AIH. Variants of the AIRE (autoimmune regulator) gene cause AIH mainly in APS-1 (autoimmune polyglandular syndrome type 1); AIRE is an essential molecule that induces self-antigen expression in the thymus to establish self-tolerance. In patients with AIRE variants, AIH appears as part of the APS-1 phenotype, characterized by anti-CYP1A2 and anti-ASGPR antibody positivity.
AIH is a rare autoimmune liver disease reported worldwide, and its prevalence and incidence vary considerably by study population and region. The most epidemiological data have accumulated for white populations in Northern Europe and North America. Studies in North America and Europe report an annual incidence of 1–2 per 100,000 population and a prevalence of 10–25 per 100,000 population. Among Alaska Natives, the incidence is unusually high at 43 per 100,000 population.
The sex distribution is markedly skewed toward women, who account for about 70–80% of all AIH patients. The female-to-male ratio is about 3.6–4:1. Age at onset is known to show a bimodal distribution, with higher frequencies in childhood to adolescence (age 10–20) and in adulthood (age 40–60), but in practice it can occur at any age. AIH is not uncommon in the elderly, and late-onset AIH tends to be diagnosed late because symptoms are atypical and cirrhosis is frequently present.
Epidemiological data from East Asia, including Korea, are limited compared with Western countries. Analyses using Korean Health Insurance Review & Assessment Service (HIRA) data show a steadily increasing number of AIH patients, which may reflect an actual increase in incidence along with improved diagnostic awareness. In Japan, the prevalence of AIH is reported at about 8–10 per 100,000 population.
AIH can also present as AIH-PBC (primary biliary cholangitis) overlap syndrome or AIH-PSC (primary sclerosing cholangitis) overlap syndrome. AIH-PBC overlap syndrome accounts for about 8–10% of all AIH and has features of both diseases simultaneously. In pediatric AIH, the proportion of AIH-PSC overlap syndrome is higher than in adults.
The core pathogenesis of AIH is hepatocyte-specific CD4+ T cell– and CD8+ cytotoxic T cell–mediated injury resulting from failure of immune self-tolerance. Normally, central tolerance in the thymus and suppression of autoreactive T cells by peripheral regulatory T cells (Tregs) are maintained, but in AIH these mechanisms break down at multiple levels.
Treg dysfunction: many studies have confirmed that the number and function of regulatory T cells (CD4+CD25+FoxP3+ Tregs) in the peripheral blood and liver are reduced in AIH patients. Normal Tregs suppress autoreactive effector T cells through secretion of IL-10 and TGF-β and through cell-to-cell contact, but in AIH this suppressive function is impaired. Interestingly, partial recovery of Treg function is observed in patients who achieve remission with steroid treatment.
CD4+ Th cells and autoantibodies: in AIH, CD4+ T helper cells differentiate into follicular helper T cells (Tfh) that help B cells, promoting IgG production. As a result, hyper-IgG-emia and various autoantibodies (ANA, anti-smooth muscle antibody ASMA, anti-LKM-1, anti-SLA/LP, etc.) are produced. Evidence that autoantibodies themselves directly cause hepatocyte injury is limited, but liver injury via an antibody-dependent cellular cytotoxicity (ADCC) mechanism has been proposed.
Presentation of hepatocyte autoantigens: intrahepatic antigen-presenting cells (APCs) expressing HLA class II molecules (DR, DQ) and activated hepatocytes present autoantigen peptides to CD4+ T cells. Hepatocytes do not normally express HLA class II, but its expression can be induced by inflammatory cytokines (particularly IFN-γ). Persistent activation of autoreactive T cells through this process sustains chronic hepatitis.
Direct cytotoxic T cell (CTL)–mediated injury: CD8+ cytotoxic T cells recognize hepatocyte autoantigens via HLA class I molecules and directly kill hepatocytes through the perforin/granzyme pathway and the Fas/FasL pathway. In AIH liver tissue, hepatocyte infiltration by CD8+ T cells and 'rosette' formation are observed as characteristic histological findings.
NK cell abnormalities: in AIH, intrahepatic natural killer (NK) cells are reduced in number, which may reflect suppression by Tregs or immune exhaustion. Impairment of the normal immune surveillance function of NK cells may contribute to the failure to eliminate autoreactive T cells.
The clinical symptoms of AIH are highly variable, spanning a broad spectrum from asymptomatic incidental discovery to acute liver failure. About 25–34% of all AIH patients are asymptomatic at diagnosis and are discovered incidentally through abnormal liver function tests.
Nonspecific systemic symptoms: fatigue is the most common symptom, reported in 85–90% of AIH patients. This fatigue may persist even after liver function improves, seriously affecting quality of life. Anorexia, weight loss, low-grade fever, arthralgia, and myalgia are also commonly present.
Hepatobiliary symptoms: right upper quadrant discomfort or dull pain, jaundice (mild to moderate initially), dark urine, and pruritus may occur. Pruritus tends to be less prominent than in PBC. In the acute presentation form, rapidly worsening jaundice, coagulopathy, and hepatic encephalopathy may be present.
Acute liver failure (ALF): about 3–6% of AIH patients present with acute liver failure, which includes both acute exacerbation of pre-existing AIH ('acute-on-chronic') and abrupt onset in patients with no prior liver disease ('true acute AIH'). AIH presenting as ALF progresses very rapidly, so prompt diagnosis and treatment are essential.
Symptoms associated with cirrhosis: when cirrhosis has already formed at diagnosis, symptoms related to portal hypertension such as ascites, lower-extremity edema, esophageal variceal bleeding, and hepatic encephalopathy may occur. About 28–38% of all AIH patients already show findings of cirrhosis at diagnosis.
Symptoms of concomitant autoimmune diseases: other autoimmune diseases are present in about 30–40% of AIH patients. AIH may be accompanied by autoimmune thyroid disease (Hashimoto thyroiditis, Graves disease), SLE, rheumatoid arthritis, ulcerative colitis, etc., and symptoms of these diseases may appear together.
There are no AIH-specific signs on physical examination, but various signs reflecting disease severity and stage may be observed. Jaundice (scleral icterus, skin jaundice) is seen during active hepatitis and is often mild to moderate. Hepatomegaly is commonly palpable in active AIH, and the liver surface may be smooth or slightly irregular. Splenomegaly appears at the cirrhotic stage with portal hypertension, and moderate or greater splenomegaly suggests the presence of esophageal varices.
General signs of chronic liver disease such as spider angiomas, palmar erythema, nail changes (leukonychia, clubbed fingers), and gynecomastia (in men) may appear. Ascites, a complication of cirrhosis, is confirmed by abdominal distension, shifting dullness, and a fluid wave. In hepatic encephalopathy, fetor hepaticus, asterixis, and altered consciousness are observed.
Relatively characteristic findings in AIH include periarticular tenderness with arthralgia (especially in HLA-DR4–associated AIH) and thyroid abnormalities (enlargement, nodules). Cushingoid features (moon face, truncal obesity, striae, hirsutism) may appear as a result of long-term steroid treatment; these are side effects of treatment rather than signs of the disease itself.
The characteristic histological findings of autoimmune hepatitis—'interface hepatitis', 'plasma cell infiltration', and 'hepatocyte rosette' formation—cannot be confirmed by physical examination and can be confirmed only by liver biopsy, but the severity of these findings generally correlates with clinical symptoms.
Large-scale population-based screening for AIH is not currently recommended. However, AIH should be suspected and actively tested for in the following clinical situations.
When the cause of liver function abnormalities is unknown: AIH is considered when there is persistent AST/ALT elevation even after other causes such as viral, alcoholic, drug-induced, nonalcoholic fatty liver disease (NAFLD/NASH), and inherited metabolic diseases have been excluded. In particular, in AIH serum aminotransferases are often markedly elevated to several hundred IU/L or more.
Screening serum tests: these include (1) liver function tests (ALT, AST, ALP, GGT, total bilirubin, direct bilirubin), (2) protein fractions — total protein, albumin, quantitative serum IgG (total immunoglobulin G), (3) an autoantibody panel — antinuclear antibody (ANA, immunofluorescence), anti-smooth muscle antibody (ASMA), anti-LKM-1 (anti-CYP2D6), anti-SLA/LP, and (4) complete blood count and coagulation prothrombin time (PT-INR).
IgG elevation is highly characteristic of AIH, and a value of 1.1 times the upper limit of normal or higher contributes to the diagnostic score. Simple quantitative IgG measurement alone is also useful for initial screening.
Autoantibodies by AIH type:
| AIH type | Characteristic autoantibodies | Clinical features |
|---|---|---|
| Type 1 AIH | ANA, ASMA (anti-F-actin) | Common in adults, associated with HLA-DR3/DR4, good steroid response |
| Type 2 AIH | Anti-LKM-1 (anti-CYP2D6), anti-LC-1 | Predominantly children to young adults, frequent acute presentation, tendency toward steroid dependence |
| (SLA/LP positive) | Anti-SLA/LP (anti-SEPSECS) | In both types 1 and 2, high diagnostic specificity, associated with relapse |
Ultrasound is performed initially to assess for cirrhosis, signs of portal hypertension, and surveillance for hepatocellular carcinoma (HCC), and is also used in follow-up.
Because there is no single specific test for AIH, diagnosis uses diagnostic criteria that integrate clinical, serological, and histological findings. The most widely used in current clinical practice is the Simplified Scoring System for AIH published by Hennes et al. in 2008.
Simplified Criteria for AIH:
| Item | Criteria | Score |
|---|---|---|
| ANA or ASMA | ≥1:40 | +1 |
| ANA or ASMA | ≥1:80 | +2 |
| Anti-LKM-1 | ≥1:40 | +2 |
| Anti-SLA/LP | Positive | +2 |
| IgG | >1× upper limit of normal | +1 |
| IgG | >1.1× upper limit of normal | +2 |
| Liver histology | Compatible with AIH | +1 |
| Liver histology | Typical of AIH | +2 |
| Viral hepatitis | Excluded | +2 |
Score interpretation: ≥6 points — probable AIH, ≥7 points — definite AIH. Autoantibody points are summed up to a maximum of 2 points only.
Role of liver biopsy: in the diagnosis of AIH, liver biopsy is essential for confirming the diagnosis, assessing histological stage (fibrosis stage), and making treatment decisions. The typical histological findings of AIH are as follows: (1) interface hepatitis — hepatocyte necrosis at the portal tract boundary with lymphocyte and plasma cell infiltration, (2) lobular hepatitis — hepatocyte necrosis and inflammatory infiltration in the centrilobular region, (3) plasma cell infiltration — an abundance of plasma cells is highly characteristic of AIH, (4) hepatocyte rosetting — regenerating hepatocytes in a tubular arrangement, (5) bridging necrosis or pericentral necrosis — in severe or acute AIH.
In AIH patients who are negative for ANA and ASMA on serological testing, if anti-SLA/LP testing is also negative, additional testing for anti-ASGPR and anti-actin–specific antibodies may be considered. MRCP (magnetic resonance cholangiopancreatography) may be performed to differentiate from PSC or to exclude AIH-PSC overlap syndrome.
The key goal of AIH treatment is to achieve and maintain complete biochemical remission (normalization of ALT/AST + normalization of IgG), thereby halting the progression of hepatic fibrosis and preventing transition to cirrhosis. The current standard first-line treatment is combination therapy with a corticosteroid and azathioprine (AZA).
First-line treatment — induction therapy: start prednisolone at 0.5–1 mg/kg/day (maximum 50 mg/day) and taper gradually over several weeks according to the serum aminotransferase response. Azathioprine at 1–1.5 mg/kg/day (usually 50–100 mg/day) is added from the start or after 1–2 weeks. TPMT (thiopurine methyltransferase) or NUDT15 genotyping is recommended before azathioprine administration, as patients deficient in these enzymes are at high risk of myelosuppressive toxicity. In particular, in East Asians including Koreans, the NUDT15 c.415C>T variant is the main predictor of azathioprine-induced leukopenia.
Budesonide combination: IAIHG studies have demonstrated that, in pre-cirrhotic AIH, budesonide 3 mg three times daily + AZA 1–2 mg/kg/day achieves remission rates equivalent to prednisolone combination therapy while significantly reducing systemic corticosteroid side effects (osteoporosis, diabetes, Cushing syndrome). However, caution is needed in cirrhotic patients with portal hypertension, because budesonide enters the systemic circulation extensively and can cause adrenal suppression.
Remission criteria and tapering: complete biochemical remission is defined as normalization of ALT/AST and IgG. After remission is achieved, discontinuation of treatment may be considered after continuing maintenance therapy for at least 2–3 years. The relapse rate is low when liver biopsy before discontinuation shows histological normalization or improvement to minimal hepatitis. However, about 50–90% of all AIH patients relapse after discontinuing treatment, so many patients require long-term maintenance treatment.
Second-line treatment — refractory AIH: in patients with an insufficient response to standard treatment or who cannot use azathioprine because of side effects, mycophenolate mofetil (MMF) 1–3 g/day is recommended as an alternative. Others, such as tacrolimus, cyclosporine, 6-mercaptopurine (6-MP), and sirolimus, have been used in small studies.
AIH with acute liver failure: for AIH presenting as ALF, high-dose corticosteroids (methylprednisolone 60–80 mg/day intravenously) should be started immediately, and if there is no response within 3–5 days, liver transplantation evaluation should proceed without delay. AIH accounts for about 4–5% of all liver transplants, and the recurrence rate of AIH after transplantation is about 23–32%.
AIH is an autoimmune liver disease that responds well to immunosuppressive treatment, and with appropriate treatment long-term survival close to that of the general population is possible. The rate of complete biochemical remission with first-line treatment is about 65–80%, and the histological remission rate is lower, at about 55–60%.
The relapse rate after discontinuation of treatment is high, with relapse observed in about 50% within 2 years and about 70–90% within 5 years. Relapse is confirmed by renewed elevation of aminotransferases and IgG, and treatment must be resumed immediately upon relapse. In patients with repeated relapses, long-term maintenance treatment (low-dose AZA or prednisolone) is standard.
Regarding the risk of progression to cirrhosis, the risk of cirrhosis and its complications (ascites, esophageal variceal bleeding, hepatic encephalopathy, hepatocellular carcinoma) increases significantly in patients who do not achieve complete remission or who relapse repeatedly. Patients who already have cirrhosis at diagnosis have lower 10-year survival than those who do not. The risk of hepatocellular carcinoma (HCC) in AIH is lower than in cirrhosis associated with viral hepatitis, but an HCC incidence of about 1–2% per year has been reported even in AIH cirrhosis, so regular liver ultrasound and AFP surveillance are recommended.
Poor prognostic factors include (1) abnormal bilirubin and INR at diagnosis or at the start of treatment, (2) advanced hepatic fibrosis/cirrhosis already present at diagnosis, (3) poor biochemical response to treatment, (4) HLA-DR3 positivity (poorer treatment response than HLA-DR4), and (5) acute or ALF presentation.
Recurrence of AIH after liver transplantation appears on average about 2–3 years later and mainly occurs after immunosuppression is reduced. Recurrent AIH can also mostly be controlled by intensifying immunosuppressive treatment, but some patients may require retransplantation because of graft failure. Five-year survival after transplantation is reported at about 86–90%.
Given the autoimmune pathogenesis of AIH, primary prevention is currently impossible. However, secondary prevention—preventing progression to cirrhosis and improving quality of life through early diagnosis and treatment—is key. Prevention of relapse through maintenance of remission (tertiary prevention) is also important.
Prevention of drug-induced AIH: when prescribing drugs that may trigger AIH, such as minocycline, nitrofurantoin, and interferon, baseline liver function should be measured beforehand and monitored regularly during treatment. If liver function abnormalities appear during administration of these drugs, immediate discontinuation and evaluation for AIH are needed.
Maintenance of remission and relapse prevention: patient education is important so that treatment is not stopped arbitrarily. When discontinuation is being considered, a stepwise tapering plan should be made after confirming that complete biochemical remission has been maintained for at least 2 years and, preferably, confirming histological normalization on liver biopsy. In cirrhotic patients in particular, treatment is almost never discontinued.
Management of concomitant autoimmune diseases: clinicians should be aware of the possibility of concomitant autoimmune thyroid disease, rheumatoid arthritis, inflammatory bowel disease, etc. in AIH patients and should carry out screening and management for these diseases in parallel. When a concomitant autoimmune disease is present, shared use of immunosuppressive drugs (e.g., use of AZA when IBD is present) is possible.
Vaccination: AIH patients receiving immunosuppressive treatment should avoid live vaccines. It is ideal to complete hepatitis A, hepatitis B, pneumococcal, and influenza vaccination before starting immunosuppressive treatment. Influenza and pneumococcal vaccination during corticosteroid treatment is generally permitted.
Hepatocellular carcinoma surveillance: in AIH patients who have progressed to cirrhosis, HCC is detected early with liver ultrasound and AFP measurement every 6 months. There is currently no standard recommendation for HCC surveillance in non-cirrhotic AIH in remission, but long-term follow-up is necessary.